Product Information

BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE is a generic product labeled by Ingenus Pharmaceuticals LLC, priced at $3.0119 per EA under NDC 50742028313. Its NADAC has been published 148 times since Jan 17, 2024.

FDA first approved this application on Jul 3, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE

Bismuth subcitrate potassium, Metronidazole, Tetracycline hydrochloride
$3.0119per EA

Strength

140; 125; 125 mg/1; mg/1; mg/1

NDC

50742028313

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

10/21/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA217511

FDA Approved

7/3/2023

TE Code

AB

On Market Since

7/4/2023

Pharmacological Classes

Price Statistics

The NADAC for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE has been published 148 times since Jan 17, 2024, and over the history we have for it it has declined 41.3%. The table below summarizes its recorded NADAC range and movement.

Current price$3.0119 per EA
All-time high$5.1282 (Feb 14, 2024)
All-time low$2.3760 (Aug 19, 2026)
52-week high$3.1850
52-week low$2.3760
Median price$3.5784
Average price$3.5020
Largest weekly change+25.3% (Oct 21, 2026)
Weeks tracked148
Tracking sinceJan 17, 2024

Price History

1W

0.0%

1M

+25.3%

3M

+26.7%

6M

+2.7%

1Y

-9.4%

3Y

N/A

5Y

N/A

All

-41.3%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Bismuth subcitrate potassium, Metronidazole, Tetracycline hydrochloride market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE, manufactured by Ingenus Pharmaceuticals LLC, is $3.0119 per EA (NDC 50742028313), effective Nov 11, 2026.

How has the price of BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE has declined 41.3%. It has been tracked across 148 weekly CMS publications since Jan 17, 2024.

What are the highest and lowest recorded NADAC prices for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?

Since Jan 17, 2024, the NADAC for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE has ranged from a low of $2.3760 (Aug 19, 2026) to a high of $5.1282 (Feb 14, 2024), with a median of $3.5784 per EA.

Are there cheaper alternatives to BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?

No other NADAC-published product currently shares the active ingredient and strength of BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?

BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE (NDC 50742028313) is labeled by Ingenus Pharmaceuticals LLC, and CMS classifies it as a generic product.